The FDA’s answer to this question is not a yes or no. The agency said: “We believe that enhancing the scientific
underpinnings of our regulation of drug quality will be more efficient and effective for both FDA and industry because it
will better target agency and industry resources to address problems that may adversely affect product quality.”
